PCS "Encouraged" By Pricing Of COX-2 Inhibitors Close To Branded NSAIDs
Executive Summary
The recent pricing of Merck's Vioxx and Searle's Celebrex close to existing branded non-steroidal anti-inflammatory drugs is evidence of some pricing restraint in the pharmaceutical industry, PCS Health Systems CEO Jean-Pierre Millon said May 3 at The Wall Street Journal Healthcare Summit in Washington, D.C.
You may also be interested in...
Rx Re-Importation Bill Impact Could Be Limited By Canadian Export Laws
Canadian export regulations would limit the impact of pharmaceutical re-importation proposals pending in Congress, a former Canadian official said at a July 24 American Enterprise Institute conference in Washington, D.C.
Rx Re-Importation Bill Impact Could Be Limited By Canadian Export Laws
Canadian export regulations would limit the impact of pharmaceutical re-importation proposals pending in Congress, a former Canadian official said at a July 24 American Enterprise Institute conference in Washington, D.C.
Africa AIDS Drug Program Relies On NGOs To Achieve Secure Distribution
Five of the major AIDS drug marketers are counting on the leading non-governmental organizations to develop secure distribution systems for drugs supplied to developing countries.